fluorobenzenes has been researched along with Sclerosis, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Csiki, Z; Dankó, K; Kerekes, G; Nagy, G; Németh, Á; Oláh, AV; Soltész, P; Szamosi, S; Szekanecz, Z; Szücs, G; Timár, O; Végh, J | 1 |
1 trial(s) available for fluorobenzenes and Sclerosis, Systemic
| Article | Year |
|---|---|
Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study.
Topics: Adult; Aged; Aged, 80 and over; Antigen-Antibody Complex; Brachial Artery; C-Reactive Protein; Carotid Intima-Media Thickness; Complement System Proteins; Electrocardiography; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation | 2013 |